MT-108
/ Eli Lilly
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 21, 2024
Morphic Demonstrates Novel Real-Time Visualization of Small Molecule α4β7 Inhibition of Gut-Trafficking Cells
(GlobeNewswire)
- "Morphic Therapeutic...announced the presentation of new data, using Spinning Disk Intravital Microscopy (IVM), that provides real-time, in vivo visualization of the impact of α4β7 inhibition on lymphocyte trafficking in mouse gut-associated lymphoid tissues (GALT). These data were presented in a poster session at Digestive Disease Week (DDW) 2024 meeting....This real-time footage and the associated data for B cell movement clearly demonstrate that MT-108, a potent and selective small molecule α4β7 inhibitor, leads to increased velocity and flux of rolling lymphocytes. This activity subsequently prevents lymphocyte migration into gut tissue, including Peyer’s patches, which is a key component of inflammatory bowel disease. Notably, MT-108 impacted B cell trafficking with similar speed of onset and efficacy as the anti-α4β7 blocking antibody DATK32, a murine analog of the monoclonal antibody vedolizumab."
Preclinical • Immunology • Inflammatory Bowel Disease
1 to 1
Of
1
Go to page
1